Federal prosecutors said Gary Johnson sold fentanyl, heroin and cocaine base across Long Island from June 2013 until November ...

We recently caught up with Nick Karls, director of compliance at Holmes Murphy and Associates, and Nathan Cassin, pharmacy ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major ...

Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.